LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Signs Renewable Energy Agreement With Georgia Power
21 sept. 2021 07h00 HE | Recro Pharma, Inc.
EXTON, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
08 sept. 2021 07h00 HE | Recro Pharma, Inc.; BioCorRx, Inc.
SAN DIEGO and ANAHEIM, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
17 août 2021 07h00 HE | Recro Pharma, Inc.
Acquisition Expands Recro’s Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth Webcast...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
13 août 2021 08h50 HE | Recro Pharma, Inc.
Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms ...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO
10 août 2021 07h00 HE | Recro Pharma, Inc.
EXTON, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Second Quarter 2021 Financial Results
09 août 2021 16h05 HE | Recro Pharma, Inc.
Q2 2021 Highlighted by Revenues of $18.0 Million, an Increase of 16% Compared to Q2 2020 Revenue Multiple New Business Agreements Continue to Expand and Diversify Customer Base and Pipeline Company...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
02 août 2021 16h05 HE | Recro Pharma, Inc.
EXTON, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Appoints Erica Raether as Vice President of People, Culture and ESG
20 juil. 2021 07h00 HE | Recro Pharma, Inc.
EXTON, Pa., July 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Enters Development and Manufacturing Agreement With New Client
13 juil. 2021 07h00 HE | Recro Pharma, Inc.
GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Inducement Grants for New Staff
07 juil. 2021 07h00 HE | Recro Pharma, Inc.
EXTON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...